PolyPid to Report Fourth Quarter 2025 Financial Results and Operational Highlights on February 11, 2026

Core Insights - PolyPid Ltd. is a late-stage biopharma company focused on improving surgical outcomes and will report its fourth quarter 2025 financial results on February 11, 2026 [1] - The company will host a conference call and webcast at 8:30 AM Eastern Time to discuss the results and business operations [1][2] Company Overview - PolyPid utilizes its proprietary PLEX (Polymer-Lipid Encapsulation matriX) technology for controlled, prolonged-release therapeutics, enabling precise drug delivery over several days to months [4] - The lead product candidate, D-PLEX100, aims to prevent abdominal colorectal surgical site infections, with a New Drug Application (NDA) submission expected in early 2026 following positive phase 3 results [4] - The company also has a pipeline focused on oncology, obesity, and diabetes [4]